Market research
SPRO Spero Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 71M
- P/E ratio
- 8.71
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 1.48
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US84833T1034
- Market cap
- 71M
- P/E ratio
- 8.71
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 1.48
About
About Spero Therapeutics Inc
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the SPRO discussion.
5 years, 4 months ago
Spero Therapeutics, Inc is currently in a long term downtrend where the price is trading 3.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.3.
Spero Therapeutics, Inc's total revenue sank by 47.5% to $2M since the same quarter in the previous year.
Its net income has increased by 25.6% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.3% to $-16M since the same quarter in the previous year.
Based on the above factors, Spero Therapeutics, Inc gets an overall score of 3/5.